Clinical Trial Update: Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating the efficacy and safety of osimertinib (AZD9291) in brain metastases from EGFR T790M-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: EGFR-TKI Resistant Mutation, Nonsmall Cell Lung Cancer | Phase 3 | Status: UNKNOWN